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ACIP is chartered as a federal advisory committee to provide expert
external advice and guidance to the Director of CDC on use of vaccines
and related agents for the control of vaccine-preventable diseases in the
civilian population of the United States. Recommendations for routine use
of vaccines in children and adolescents are harmonized to the greatest extent
possible with recommendations made by the American Academy of Pediatrics
(AAP), the American Academy of Family Physicians (AAFP), and the
American College of Obstetricians and Gynecologists. Recommendations for
routine use of vaccines in adults are reviewed and approved by the American
College of Physicians (ACP), AAFP, the American College of Obstetricians
and Gynecologists, and the American College of Nurse-Midwives. ACIP
recommendations adopted by the CDC Director become agency guidelines
on the date published in MMWR.
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1. Hiberix can be administered as early as age 12 months, in accordance
with Hib vaccination schedules for routine and catch-up immunization,
to facilitate timely booster vaccination;
2. in certain situations, patients at increased risk for invasive Hib disease
who are fully vaccinated need additional doses of Hib vaccine; and
3. unimmunized older children, adolescents, and adults with certain
specified medical conditions should receive Hib vaccine.

Front cover photo: Photomicrograph of Haemophilus influenzae as seen using a Gram-stain technique (Photo/CDC).
The MMWR series of publications is published by the Center for Surveillance, Epidemiology, and Laboratory Services, Centers for Disease Control and Prevention (CDC),
U.S. Department of Health and Human Services, Atlanta, GA 30333.
Suggested Citation: [Author names; first three, then et al., if more than six.] [Title]. MMWR 2014;63(No. RR-#):[inclusive page numbers].

Centers for Disease Control and Prevention

Thomas R. Frieden, MD, MPH, Director
Harold W. Jaffe, MD, MA, Associate Director for Science
Joanne Cono, MD, ScM, Director, Office of Science Quality
Chesley L. Richards, MD, MPH, Deputy Director for Public Health Scientific Services
Michael F. Iademarco, MD, MPH, Director, Center for Surveillance, Epidemiology, and Laboratory Services

MMWR Editorial and Production Staff (Serial)

John S. Moran, MD, MPH, Acting Editor-in-Chief
Christine G. Casey, MD, Editor
Teresa F. Rutledge, Managing Editor
David C. Johnson, Lead Technical Writer-Editor
Jeffrey D. Sokolow, MA, Project Editor

Martha F. Boyd, Lead Visual Information Specialist
Maureen A. Leahy, Julia C. Martinroe,
Stephen R. Spriggs, Terraye M. Starr
Visual Information Specialists
Quang M. Doan, MBA, Phyllis H. King
Information Technology Specialists

MMWR Editorial Board

William L. Roper, MD, MPH, Chapel Hill, NC, Chairman
Matthew L. Boulton, MD, MPH, Ann Arbor, MI
Timothy F. Jones, MD, Nashville, TN
Virginia A. Caine, MD, Indianapolis, IN
Rima F. Khabbaz, MD, Atlanta, GA
Barbara A. Ellis, PhD, MS, Atlanta, GA
Dennis G. Maki, MD, Madison, WI
Jonathan E. Fielding, MD, MPH, MBA, Los Angeles, CA
Patricia Quinlisk, MD, MPH, Des Moines, IA
David W. Fleming, MD, Seattle, WA
Patrick L. Remington, MD, MPH, Madison, WI
William E. Halperin, MD, DrPH, MPH, Newark, NJ
William Schaffner, MD, Nashville, TN
King K. Holmes, MD, PhD, Seattle, WA

Recommendations and Reports

Prevention and Control of Haemophilus influenzae Type b Disease
Recommendations of the
Advisory Committee on Immunization Practices (ACIP)
Prepared by
Elizabeth C. Briere, MD1
Lorry Rubin, MD2
Pedro L. Moro, MD3
Amanda Cohn, MD1
Thomas Clark, MD1
Nancy Messonnier, MD1
1Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, CDC
2 Steven and Alexandra Cohen Children’s Medical Center of New York, New Hyde Park, New York
3Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, CDC

Summary
This report compiles and summarizes all recommendations from CDC’s Advisory Committee on Immunization Practices (ACIP)
regarding prevention and control of Haemophilus influenzae type b (Hib) disease in the United States. As a comprehensive
summary of previously published recommendations, this report does not contain any new recommendations; it is intended for use
by clinicians, public health officials, vaccination providers, and immunization program personnel as a resource. ACIP recommends
routine vaccination with a licensed conjugate Hib vaccine for infants aged 2 through 6 months (2 or 3 doses, depending on vaccine
product) with a booster dose at age 12 through 15 months. ACIP also recommends vaccination for certain persons at increased
risk for Hib disease (i.e., persons who have early component complement deficiencies, immunoglobulin deficiency, anatomic or
functional asplenia, or HIV infection; recipients of hematopoietic stem cell transplant; and recipients of chemotherapy or radiation
therapy for malignant neoplasms). This report summarizes current information on Hib epidemiology in the United States and
describes Hib vaccines licensed for use in the United States. Guidelines for antimicrobial chemoprophylaxis of contacts of persons
with Hib disease also are provided.

Introduction
Before 1985, Haemophilus influenzae type b (Hib) was the
leading cause of bacterial meningitis and a common cause of
other invasive diseases (e.g., epiglottitis, pneumonia, septic
arthritis, cellulitis, purulent pericarditis, and bacteremia)
among U.S. children aged <5 years (1). Meningitis occurred in
approximately two thirds of children with invasive Hib disease;
15%–30% of survivors had hearing impairment or severe
permanent neurologic sequelae. Approximately 4% of all
cases were fatal (2). The first polysaccharide Hib vaccine was
introduced in the United States in 1985, followed by conjugate
Hib vaccines in 1987 and 1989. During 1989–2000, the
annual incidence of invasive Hib disease in children aged <5
years decreased by 99%, to less than one case per 100,000
children (3–7). During 2000–2012, the average annual
incidence rate of invasive Hib disease in children aged <5 years
Corresponding preparer: Elizabeth C. Briere, MD, National Center
for Immunization and Respiratory Diseases, CDC, 1600 Clifton Road
NE, MS C-09, Atlanta, GA 30333. E-mail: ebriere@cdc.gov.

in the United States remained below the Healthy People 2020
goal of 0.27/100,000 (8) (data available at http://www.cdc.gov/
abcs/reports-findings/surv-reports.html) (Figures 1 and 2).
Studies have demonstrated that vaccination with Hib conjugate
vaccine leads to decreases in oropharyngeal colonization
among both vaccinated and unvaccinated children (9–11);
the prevalence of Hib carriage has decreased among preschoolaged children from 2%–7% in the prevaccine era to <1% in
the vaccine era (9,12).
Several Hib-containing vaccines have been licensed since the
initial Advisory Committee on Immunization Practices (ACIP)
recommendations on prevention and control of Hib disease
published in 1993 (13); subsequent publications have provided
additional data and updated recommendations for these vaccines
(14–17). This report summarizes previously published ACIP
recommendations on prevention and control of Hib disease in
immunocompetent and high-risk populations (14–18); it does
not contain new recommendations and is intended as a resource
for clinicians, public health officials, vaccination providers,
and immunization program personnel. In addition, this report
summarizes current information on Hib epidemiology in the
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FIGURE 1. Estimated annual incidence* of invasive Haemophilus influenzae type b (Hib) disease in children aged <5 years — United States,
1980–2012
30
First polysaccharide Hib vaccine licensed
for use in children aged ≥18 months
First conjugate Hib vaccine licensed for
use in children aged ≥18 months

25

First Hib vaccines licensed for use in
infants aged ≥2 months

Incidence

20

15

10

5

0
1980

1982

1984

1986

1988

1990

1992

1994

1996

1998

2000

2002

2004

2006

2008

2010

2012

Year
Sources: 1980–1997: National Bacterial Meningitis Reporting System and National Notifiable Diseases Surveillance (NNDSS) data; Adams WG, Deaver KA, Cochi SL,
et al. Decline of childhood Haemophilus influenzae Type b (Hib) disease in the Hib vaccine era. JAMA 1993;269:221–6; CDC. Progress toward elimination of Haemophilus
influenzae type b disease among infants and children—United States, 1987–1995. MMWR 1996;45:901–6; CDC. Progress toward elimination of Haemophilus influenzae
type b disease among infants and children—United States, 1987–1997. MMWR 1998;47:993–8. 1998–2009: NNDSS and Active Bacterial Core Surveillance (ABCs) data.
2010–2012: ABCs cases estimated to the U.S. population.
* Per 100,000 population.

United States and describes Hib vaccines licensed for use in the
United States. Guidelines for antimicrobial chemoprophylaxis
of contacts of persons with Hib disease also are provided.

Methods
ACIP’s Meningococcal and Haemophilus influenzae type b
Work Group* comprises a diverse group of health-care providers
and public health officials. The Work Group includes
professionals from academic medicine (pediatrics, family
medicine, internal medicine, and infectious disease specialists),
federal and state public health professionals, and representatives
of professional medical organizations.
Published Hib vaccine recommendations were the primary
sources of data used by the Work Group in summarizing
recommendations for the prevention and control of Hib disease,
including the evidence-based 2013 Infectious Diseases Society
* A list of the members of the Work Group appears on page 14.
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of America clinical practice guideline for vaccination of the
immunocompromised host (17–23). Surveillance data came from
the Active Bacterial Core surveillance (ABCs) system and the
National Notifiable Diseases Surveillance System (NNDSS) (24).
Data on the immunogenicity and safety of current licensed
and available Hib vaccines were summarized on the basis of
findings from a literature search of PubMed and Web of Science
databases that was completed on April 2, 2012. A nonsystematic
review was conducted for studies on safety, effectiveness, and
immunogenicity of the current Hib vaccines published from
the time of vaccine licensure through March 2012. Because
MenHibRix was licensed in June 2012, studies published
before licensure also were reviewed. The literature search
included clinical trials, randomized controlled trials, controlled
clinical trials, evaluation studies, and comparative studies
conducted worldwide and published in English. The Vaccine
Adverse Events Reporting System (VAERS) (available at http://
www.vaers.hhs.gov) also was searched for postlicensure safety
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FIGURE 2. Estimated annual incidence* of invasive Haemophilus influenzae Type b
infection in children aged <5 years — United States, 2000–2012
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Sources: National Notifiable Diseases Surveillance and Active Bacterial Core Surveillance (ABCs) data.
* Per 100,000 population.

Background
H. influenzae is a species of bacteria that has encapsulated
(typeable) or unencapsulated (nontypeable) strains. Encapsulated
strains express one of six antigenically distinct capsular
polysaccharides (types a, b, c, d, e, or f ). Encapsulated
H. influenzae nontype b strains, particularly type a, can cause
invasive disease similar to Hib disease (25,26). Nontypeable
strains also can cause invasive disease but more commonly
cause mucosal infections such as otitis media, conjunctivitis,
and sinusitis. Hib vaccines only protect against H. influenzae
type b strains; no vaccines against nontype b or nontypeable
strains currently are available. H. influenzae colonizes the upper
respiratory tract of humans and is transmitted person-to-person
by inhalation of respiratory droplets or by direct contact with
respiratory tract secretions.
The majority of Hib disease in the United States occurs
among unimmunized and underimmunized infants and
children (those who have an incomplete primary series or
are lacking a booster dose) and among infants too young
to have completed the primary immunization series (27)
(Figure 3). Although rare, Hib disease after full vaccination
with the primary series and booster dose does occur; among
Hib case-patients aged <5 years with age-appropriate vaccine
status reported during 2002–2012 in the United States,
16% had completed the primary Hib series, and 43% had
completed the full Hib series (Figure 3). Hib disease is
uncommon in adults and in children aged >5 years. Additional
information about H. influenzae disease is available at http://
www.cdc.gov/hi-disease.

Persons with certain immunocompromising conditions are
considered at increased risk for invasive Hib disease; these
conditions might include:
• functional or anatomic asplenia,
• HIV infection,
• immunoglobulin deficiency including immunoglobulin G2
subclass deficiency,
• early component complement deficiency,
• receipt of a hematopoietic stem cell transplant, or
• receipt of chemotherapy or radiation therapy for malignant
neoplasms.
Children who develop Hib disease despite appropriate
vaccination should be evaluated for an immunological
deficiency that predisposes them to Hib disease (28).
Historically, American Indian/Alaska Native (AI/AN)
populations have had higher rates of Hib disease and
colonization than the general U.S. population, with a peak
in disease at a younger age (4–6 months) than among other
U.S. infant populations (6–7 months) (29–31). Before
introduction of vaccine in 1985, rates among AN children were
five times higher than rates among non-AN children in Alaska
(4). Although rates of Hib disease among AI/AN children
have decreased in the postvaccine era, they remain higher than
among non-AI/AN children. During 1998–2009, the average
annual incidence of Hib disease in children aged <5 years in the
United States was 8–10 times higher among AI/AN children
(1.3/100,000) than it was among white (0.16/100,000) and
black (0.12/100,000) children, respectively (27).
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The first Hib vaccine licensed for use in the United States
in 1985 was a monovalent vaccine consisting of purified
polyribosylribitol phosphate (PRP) capsular material from
type b strains. Although the vaccine was highly effective
in trials in Finland among children aged ≥18 months,
postmarketing effectiveness studies in the United States
demonstrated variable effectiveness (-69%–88%) (32). PRP
vaccines were ineffective in children aged <18 months because
of the T lymphocyte-independent nature of the immune
response to PRP polysaccharide (13). Conjugation of the PRP
polysaccharide with protein carriers that contain T-lymphocyte
epitopes confers T-lymphocyte-dependent characteristics to the
vaccine. This conjugation enhances the immunologic response
to the PRP antigen, particularly in young infants, and results
in immunologic memory (e.g., anamnestic response) (33).
Studies have suggested that long-term protection from invasive
Hib disease is correlated with the presence of anti-PRP levels
≥0.15 µg/ml in unvaccinated children and anti-PRP levels
≥1.0 µg/ml in vaccinated children (34,35).
By 1989, three monovalent Hib conjugate vaccines were
licensed for use among children aged ≥15 months (29). In late
1990, two of these conjugate vaccines were licensed for use
among infants (36,37). Since 1990, additional Hib vaccines
from numerous manufacturers have been licensed and are
currently used in the United States, including monovalent
Hib conjugate vaccines and combination vaccines that contain
a Hib conjugate vaccine. No polysaccharide Hib vaccines are
used currently in the United States.

Current Licensed and Available Hib
Monovalent Conjugate Vaccines
As of January 1, 2014, three monovalent PRP polysaccharideprotein conjugate vaccines had been licensed by the Food
and Drug Administration (FDA) and were available in the
United States: PRP-OMP (PedvaxHIB, Merck and Co., Inc.,
Whitehouse Station, New Jersey), PRP-T (ActHIB, Sanofi
Pasteur, Inc., Swiftwater, Pennsylvania), and PRP-T (Hiberix,
GlaxoSmithKline, Research Triangle Park, North Carolina)
(38) (Table 1).
In December 1990, PRP-OMP (PedvaxHIB) was licensed by
FDA as a 2-dose primary series for infants at ages 2 and 4 months,
with a booster dose (dose 3) at age 12 months (39). PRP-OMP
contains purified PRP conjugated with an outer membrane protein
complex (OMPC) of the B11 strain of Neisseria meningitidis
serogroup B. Further information is available in the package insert
at http://www.fda.gov/downloads/BiologicsBloodVaccines/
Vaccines/ApprovedProducts/UCM253652.pdf.

4
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FIGURE 3. Percentage of children aged <5 years with cases of invasive
Haemophilus influenzae type b (Hib) disease,* by vaccine status —
United States 2002–2012
45
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Sources: Active Bacterial Core surveillance system and National Notifiable
Diseases Surveillance System.
* N = 265. An additional 57 children aged <5 years with Hib had unknown vaccine
status and were excluded.
† Among those with age-appropriate vaccine status, 41% were too young to
complete the primary series, 16% completed the primary series, and 43%
completed the full series.

In March 1993, PRP-T (ActHIB) was licensed by FDA as
a 3-dose primary series for infants at ages 2, 4, and 6 months,
with a booster dose (dose 4) at age 15 months (40). This
vaccine contains purified PRP conjugated with tetanus toxoid.
Further information is available in the package insert at http://
www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/
ApprovedProducts/UCM109841.pdf.
In August 2009, PRP-T (Hiberix) was licensed by FDA for
use as the booster dose (which will be dose 3 or 4, depending
on vaccine type used for primary series) of the Hib vaccine
series for children aged 15 months through 4 years who have
received a Hib primary series (16). This vaccine contains
purified PRP conjugated with tetanus toxoid. Further
information is available in the package insert at http://
www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/
ApprovedProducts/UCM179530.pdf.

Current Licensed and Available Hib
Combination Conjugate Vaccines
As of January 1, 2014, three combination vaccines that contain
an H. influenzae type b conjugate vaccine had been licensed by
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TABLE 1. Haemophilus influenzae type b (Hib) conjugate vaccines licensed and available in the United States as of January 2014
Vaccine product

Manufacturer

Trade Name

Monovalent vaccine
PRP-OMP*,†
PRP-T
PRP-T

Merck & Co, Inc
sanofi pasteur
GlaxoSmithKline

PedvaxHIB
ActHIB
Hiberix

Combination vaccine
PRP-OMP-HepB*,†
DTaP-IPV/PRP-T
MenCY/PRP-T**

Merck & Co, Inc
sanofi pasteur
GlaxoSmithKline

Comvax
Pentacel
MenHibRix

Components

Primary series

Booster dose

PRP conjugated to OMP
PRP conjugated to tetanus toxoid
PRP conjugated to tetanus toxoid

2, 4 mos
2, 4, 6 mos
Not licensed for
primary series

12–15 mos
12–15 mos
12–15 mos§

PRP-OMP + hepatitis B vaccine
DTaP-IPV + PRP-T
MenCY + PRP-T

2, 4 mos
2, 4, 6 mos
2, 4, 6 mos

12–15 mos
15–18 mos¶
12–15 mos

Source: Adapted from American Academy of Pediatrics. Haemophilus influenzae infections. Pickering L, Baker C, Kimberlin D, Long S, eds. Red book: 2012 report of
the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2012:345–52.
* If a PRP-OMP vaccine is not administered as both doses in the primary series, or if there is uncertainty about which products were administered previously, a third
dose of Hib conjugate vaccine is needed to complete the primary series.
† Preferred vaccine for American Indian/Alaska Native children.
§ To facilitate timely booster vaccination, Hiberix can be administered as early as age 12 months, in accordance with Hib vaccination schedules for routine and catchup immunization (CDC. Licensure of a Haemophilus influenzae type b [Hib] vaccine [Hiberix] and updated recommendations for use of Hib vaccine. MMWR
2009;58:1008–9).
¶ The booster dose may be administered as early as age 12 months, provided that at least 6 months have elapsed since the third dose.
** Recommendations for the MenCY component of MenCY/PRP-T have been published previously (CDC. Infant meningococcal vaccination: Advisory Committee on
Immunization Practices (ACIP) recommendations and rationale. MMWR 2013;62:52–4).

FDA and were available in the United States: PRP-OMP/HepB
(Comvax, Merck and Co., Inc., Whitehouse Station, New
Jersey), DTaP-IPV/PRP-T (Pentacel, Sanofi Pasteur, Inc.,
Swiftwater, Pennsylvania), and MenCY/PRP-T (MenHibRix,
GlaxoSmithKline, Inc., Rixensart, Belgium) (38) (Table 1).
In October 1996, PRP-OMP/HepB (Comvax) was licensed
by FDA for vaccination against invasive Hib disease and
hepatitis B infection in infants at ages 2, 4, and 12 through 15
months (14). This vaccine includes the antigenic components
used in PedvaxHIB (PRP-OMP) and Recombivax HB
(hepatitis B surface antigen). Further information is available
in the package insert at http://www.fda.gov/downloads/
BiologicsBloodVaccines/Vaccines/ApprovedProducts/
UCM109869.pdf.
In June 2008, DTaP/IPV/PRP-T (Pentacel) was licensed by
FDA for vaccination against invasive Hib disease, diphtheria,
tetanus, pertussis, and poliomyelitis in infants at ages 2, 4, 6,
and 15 through 18 months (15). It is not indicated for the
DTaP/IPV booster dose at age 4 through 6 years. The vaccine
includes the antigenic components used in ActHIB (PRP-T) and
Poliovax. Further information is available in the package insert
at http://www.fda.gov/downloads/BiologicsBloodVaccines/
Vaccines/ApprovedProducts/UCM109810.pdf.
In June 2012, MenCY/PRP-T (MenHibRix) was licensed
by FDA for vaccination against invasive Hib disease and
N. meningitidis serogroups C and Y disease in infants at ages 2,
4, 6, and 12 through 15 months (17). Infants at increased risk
for meningococcal disease† should be vaccinated with a 4-dose
† Infants

with persistent complement component deficiencies, those with
functional or anatomic asplenia (including sickle cell disease), healthy infants
in communities with a meningococcal disease outbreak for whom vaccination
is recommended, and infants traveling to or residing in areas with hyperendemic
or epidemic meningococcal disease.

series of MenCY/PRP-T. Routine meningococcal vaccination
is recommended only for infants who are at increased risk
for meningococcal disease. However, MenCY/PRP-T may
be used in any infant for routine vaccination against Hib.
Further recommendations for use of the MenCY component of
MenCY/PRP-T have been published previously (17). Further
vaccine information is available in the package insert at http://
www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/
ApprovedProducts/UCM308577.pdf.

Immunogenicity of Current Licensed and
Available Hib Vaccines
Protective antibody levels are detected for both PedvaxHib
and ActHib after a primary series (41–43). However, the
vaccines differ in the timing of antibody response. PedvaxHib
produces a substantial antibody response after the first
dose with an additional boost in geometric mean antibody
concentration after the second or third dose (41,42,44–46).
Therefore, PedvaxHib is licensed as a 2-dose primary series.
PedvaxHib effectiveness was 93%–100% in Navajo infants
vaccinated with a 2-dose series (13,41,47).
Geometric mean antibody concentrations remain at or
below 1.0 µg/ml after the first and second dose of ActHIB,
but a protective antibody response is seen after the third dose
(41,42,45,48,49). Effectiveness studies for ActHIB were
terminated early in the United States with licensure of the first
Hib conjugate vaccine; no cases of invasive Hib disease were
reported among vaccinees at the time of study termination
(13,47). A prospective controlled trial of PRP-T among
56,000 subjects in the United Kingdom found an effectiveness
of 95% (95% confidence interval [CI] = 74%–100%) (47).
MMWR / February 28, 2014 / Vol. 63 / No. 1
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Antibody levels decline after completion of the primary series
with PRP-T and PRP-OMP vaccines and a booster dose at age
12–15 months is necessary to maintain protective antibody
levels. Booster doses of PedvaxHib, ActHib, and Hiberix at age
12–15 months provide levels of antibody that are protective
against invasive Hib disease (16,44,46,48,50,51).
Protective antibody responses comparable to those detected
after receipt of separately administered PedVaxHIB and
Recombivax HB vaccines are seen after the second primary
dose and booster dose of Comvax vaccine (14,52). Pentacel
and MenHibRix induce protective antibody responses that are
noninferior to separately administered PRP-T vaccines after
the third primary dose and booster dose (53–59).
No clinically significant immune interference has been observed
with any of the available monovalent or combination Hib vaccines
and concomitant administration of other routine childhood
vaccines (51,52,60–67; ACIP, unpublished data, 2009).

Safety of Current Licensed and
Available Hib Vaccines
In prelicensure trials, adverse reactions to PedvaxHib, ActHib,
and Hiberix were uncommon, usually mild, and generally
resolved within 12–24 hours (16,41,43,46,49,50). Rates of
adverse reactions to Comvax, Pentacel, and MenHibRix were
similar to those seen with separately administered vaccines
(14,52–54,68).
Postmarketing surveillance for adverse events following
receipt of Hib vaccines has been conducted primarily by two
systems in the United States: VAERS and the Vaccine Safety
Datalink (VSD). VAERS is a national passive surveillance
system operated jointly by CDC and FDA that receives reports
of adverse events following vaccination from health-care
personnel, manufacturers, vaccine recipients, and others (69).
VAERS can generate, but not test, vaccine safety hypotheses
and is subject to several limitations, including reporting biases
and inconsistent data quality (69). VSD is a collaboration
between CDC and nine integrated health-care organizations
that conducts population-based vaccination safety studies to
assess hypotheses that arise from review of medical literature,
reports to VAERS, changes in immunization schedules, or
introduction of new vaccines (70).

Safety Data Reported to VAERS
During January 1, 1990–May 31, 2013, VAERS received
29,047 reports involving receipt of Hib vaccines (PedvaxHIB,
ActHIB, Hiberix, Comvax, and Pentacel) in the United States;
26,375 (91%) reports involved children aged <2 years.
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Hib vaccines were administered concurrently with one or
more other vaccines in 95% of case reports. The median
time from vaccination to onset of an adverse event was
1 day. The most frequently reported adverse events were
fever (31%), crying (11%), injection site erythema (11%),
irritability (10%), and rash (9%).
Among all Hib vaccines reports, approximately 17% were
coded as serious as defined in the Code of Federal Regulations
(71) (i.e., report contained information that the event led to
death, life-threatening illness, hospitalization, prolongation
of hospitalization, or permanent disability). Among the
5,062 reports coded as serious, the most frequent adverse
events were fever (37%), vomiting (21%), convulsion (20%),
irritability (17%), and intussusception (11%). In 97% of the
intussusception reports, rotavirus vaccine was administered
concomitantly and might have prompted reporting of this
adverse event.
VAERS received reports of 878 deaths following Hib
containing vaccines that occurred during January 1, 1990–
May 31, 2013. An autopsy report or other medical records
was available for 620 (71%) of these deaths, among which
the most frequent cause of death was sudden infant death
syndrome (52%). Other causes of death included respiratory
(9%), cardiovascular (5%), infectious (5%), neurologic (3%),
and gastrointestinal (2%) conditions. In 14% of reports, the
cause was undetermined, and in 11% of reports, various other
causes were reported (e.g., asphyxia and blunt force trauma).
The reporting frequencies for Hib containing vaccines are
similar to what has been observed with other recommended
childhood vaccines. No unusual or unexpected safety patterns
were observed in VAERS data for any Hib vaccines.

Population-Based Safety Findings
No postlicensure safety studies of monovalent Hib vaccines
were identified by the literature review. However, the VSD
conducted an observational study of the combination
Hib vaccine, DTaP-IPV-Hib (Pentacel), for the period
September 2008–January 2011 (55). Compared with
children who received DTaP-containing control vaccine
(i.e., without Hib), children aged 1–2 years who received
DTaP-IPV-Hib vaccine had an elevated risk for fever
(RR = 1.83; 95% CI = 1.34–2.50). DTaP-IPV-Hib vaccine
was not associated with any other medically attended adverse
health event.
An independent postmarketing safety evaluation of
Hib-HepB (Comvax) was conducted by a managed care
organization in Seattle, Washington, for the period July 1997–
December 2000 (72). Using ICD-9 codes, the retrospective
cohort study evaluated adverse events reported 1–30 days
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following administration of Hib-HepB, compared with
rates of adverse events among two control groups (historical
control group and self-comparison group). A total of 27,802
vaccine doses were administered during the study period
with 111,129 diagnoses recorded within 0–30 days following
administration of Comvax in any health-care setting. There
were 127 separate adverse event codes with significant elevated
relative risks and 66 codes with significantly decreased relative
risks (p<0.5). On medical record review, there was no consistent
pattern to respiratory or gastrointestinal illnesses; fever findings
appeared to be explained by changes in data collection or by
concomitant vaccination with measles, mumps, and rubella
virus vaccine. Two deaths occurred within the study period,
both of which were considered unrelated to vaccination. No
consistent association was identified between serious adverse
events and vaccination with Hib-HepB, and the vaccine had
a favorable safety profile.

Recommendations for Hib Vaccine Use
Recommendations for Routine Vaccination
ACIP recommends routine administration of a conjugate Hib
vaccine series (monovalent vaccine [PedvaxHib (PRP-OMP)
or ActHib (PRP-T)] or Hib vaccine in combination with
HepB [Comvax], DTaP/IPV [Pentacel], or MenCY [MenHibRix])
beginning at age 2 months. Infants aged 2–6 months should
receive a 3-dose series of Hib PRP-T as ActHib, Pentacel, or
MenHibRix or a 2-dose series of Hib PRP-OMP as PedvaxHib
or Comvax (Table 1). The first dose can be administered as
early as age 6 weeks. A booster dose (which will be dose 3 or
4 depending on vaccine type used in primary series) of any
licensed conjugate Hib vaccine (monovalent vaccine [PedvaxHib
(PRP-OMP), ActHib (PRP-T), or Hiberix (PRP-T)] or Hib
vaccine in combination with HepB [Comvax] or DTaP/IPV
[Pentacel] or MenCY [MenHibRix]) is recommended at age 12
through 15 months and at least 8 weeks after the most recent
Hib vaccination (Table 1).
Hib vaccine has been found to be immunogenic in
patients with immunocompromising conditions although
immunogenicity varies with the degree of immunocompetence
(13,73–84). Patients at increased risk for invasive Hib disease
who are vaccinated (have received a Hib primary series and a
booster dose at age ≥12 months) do not need further routine
immunization, except in certain situations (Table 2).

Guidance for Hib Vaccine Use
Guidance for Routine Vaccination
Doses for either primary series (2-dose or 3-dose) should be
administered 8 weeks apart; however, if necessary, an interval
of 4 weeks between doses is acceptable. If a PRP-OMP vaccine
(PedvaxHIB or Comvax) is administered for both doses in
the primary series, a third primary dose is not indicated. If a
PRP-OMP vaccine (PedvaxHib or Comvax) is not administered
for both doses in the primary series or there is uncertainty
about which products were administered previously, a third
primary series dose of a Hib conjugate vaccine is needed to
complete the primary series. Any monovalent or combination
Hib conjugate vaccine is acceptable for the booster dose
(dose 3 or 4 depending on vaccine type used in primary
series), regardless of the product used for the primary series.
Hiberix should be used only for the booster dose (dose 3 or 4,
depending on the vaccine type used for primary series) in
children aged 12 months through 4 years who have received
at least 1 dose of Hib vaccine previously.

Guidance for Catch-up Schedules
If the first vaccination is delayed by >1 month, the
recommended catch-up schedule (available at http://www.
cdc.gov/vaccines/schedules/hcp/child-adolescent.html) should
be followed.
• For unvaccinated infants receiving the first dose at age
<7 months, 2 doses of PRP-OMP or 3 doses of PRP-T
vaccine should be administered with a minimum of a
4-week interval between doses. A booster dose (dose 3 or 4
depending on vaccine type used for primary series) at age
12 through 15 months is necessary only if 2 or 3 primary
doses (depending on vaccine type used) were administered
before age 12 months.
• For unvaccinated infants receiving the first dose at age
7 through 11 months, a second dose should be administered
at least 4 weeks later (regardless of Hib conjugate vaccine
[PRP-T or PRP-OMP] used for first dose). A third (and
final) dose should be administered at age 12 through
15 months or 8 weeks after the second dose, whichever
date is later.
• For unvaccinated children receiving the first dose at age
12 through 14 months, a second dose of any monovalent
or combination Hib conjugate vaccine should be
administered 8 weeks after the first dose. A third dose is
not necessary.
• For unvaccinated children receiving the first dose at age
15 through 59 months, no further doses of any monovalent
or combination Hib conjugate vaccine are indicated.
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TABLE 2. Guidance for Haemophilus influenzae type b (Hib) vaccination in high-risk groups
High-risk group*

Hib vaccine guidance

Patients aged <12 mos

Follow routine Hib vaccination recommendations

Patients aged 12–59 mos

If unimmunized or received 0 or 1 dose before age 12 mos: 2 doses, 8 wks apart
If received ≥2 doses before age 12 mos: 1 dose 8 wks after last dose
If completed a primary series and received a booster dose at age ≥12 mos: no additional doses

Patients aged <60 months undergoing
chemotherapy or radiation therapy†

If routine Hib doses administered ≥14 days before starting therapy: revaccination not required
If dose administered within 14 days of starting therapy or given during therapy:
repeat doses starting at least 3 mos following therapy completion

Patients aged ≥15 mos undergoing
elective splenectomy

If unimmunized:§ 1 dose prior to procedure¶

Asplenic patients aged >59 mos and adults

If unimmunized:§ 1 dose

HIV-infected children aged ≥60 mos

If unimmunized:§ 1 dose

HIV-infected adults

Hib vaccination is not recommended

Recipients of hematopoietic stem cell
transplant, all ages

Regardless of Hib vaccination history: 3 doses (at least 4 wks apart) beginning 6–12 mos
after transplant

* Persons with functional or anatomic asplenia, HIV infection, immunoglobulin deficiency including immunoglobulin G2 subclass deficiency, or early component
complement deficiency, recipients of a hematopoietic stem cell transplant, and those receiving chemotherapy or radiation therapy for malignant neoplasms.
† Some experts suggest conducting serologic testing for these patients (Source: Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for
vaccination of the immunocompromised host. Clin Infect Dis 2013;[Epub ahead of print] doi: 10.1093/cid/cit684).
§ Patients who have not received a primary series and booster dose or at least 1 dose of Hib vaccine after 14 months are considered unimmunized.
¶ Some experts suggest vaccination at least 14 days before the procedure (Sources: CDC. General recommendations on immunization: recommendations of the
Advisory Committee on Immunization Practices [ACIP]. MMWR 2011;60[No. RR-2]; CDC. Recommendations of the Advisory Committee on Immunization Practices
(ACIP): use of vaccines and immune globulins in persons with altered immunocompetence. MMWR 1993;42[No. RR-4]; Rubin LG, Levin MJ, Ljungman P, et al. 2013
IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2013;[Epub ahead of print] doi: 10.1093/cid/cit684.) Some experts
suggest administering a dose prior to elective splenectomy regardless of prior vaccination history (Source: American Academy of Pediatrics. Haemophilus influenzae
infections. In: Pickering L, Baker C, Kimberlin D, Long S, eds. Red book: 2012 report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy
of Pediatrics; 2012:345–52).

• Previously unvaccinated children aged ≥60 months who are
not considered high-risk generally are immune to Hib disease
and do not require catch-up vaccination.
The recommended catch-up schedule should be followed
for children aged <12 months who are at increased risk for
Hib disease and have delayed or no Hib vaccination. Catch-up
guidance for children aged 12 through 59 months who are
at increased risk for Hib disease and who have delayed or no
Hib vaccination is described below (see “High-risk groups”;
Table 2).

Guidance for Vaccinating
Special Populations
American Indians/Alaska Natives
Hib meningitis incidence peaks at a younger age (4–6 months)
among AI/AN infants than among other U.S. infant populations
(6–7 months) (29–31). Vaccination with a 2 dose primary series of
a Hib vaccine that contains PRP-OMP (PedvaxHIB or Comvax)
is preferred for AI/AN infants to provide early protection because
these vaccines produce a protective antibody response after
the first dose (41–43,51,52,85). If the first vaccination dose
is delayed by >1 month, the recommended catch-up schedule
(available at http://www.cdc.gov/vaccines/schedules/hcp/childadolescent.html) should be followed. A booster dose (dose 3)
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of Hib vaccine is recommended at age 12 through 15 months;
for the booster dose, there is no preferred vaccine formulation
(i.e., any licensed Hib conjugate vaccine is acceptable). The
importance of this early protection was demonstrated in Alaska
(30,86). During July 1991–January 1996, a PRP-OMP vaccine
was used statewide in Alaska and a >90% decrease in Hib disease
rates occurred among AN and nonnative children (30,86).
During 1996–1997, after the statewide vaccine was changed to a
combination vaccine that included a non-OMP Hib component,
Hib incidence increased significantly (19.8 to 91.1 cases/100,000
children aged <5 years, p<0.001) among AN children while
remaining unchanged among nonnative children (30,86).
Disease reappearance seemed to be attributable to the use of
a Hib vaccine that did not achieve early protective antibody
concentrations in children who had ongoing exposure to Hib
via oropharyngeal colonization among close contacts. After
returning to the use of PRP-OMP containing vaccines in Alaska,
the incidence of Hib disease in AN children decreased to rates of
fewer than six cases per 100,00 children aged <5 years (30,86).

Children Aged <24 Months with Invasive
Hib Disease
Children aged <24 months who develop invasive Hib disease
can remain at risk for developing a second episode because
natural infection in this age group does not reliably result in
development of protective antibody levels. These children
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should be considered unvaccinated regardless of previous
Hib vaccination and should receive Hib vaccine doses
according to the age-appropriate schedule for unimmunized
children (28,87–89). Children aged <24 months who develop
invasive Hib disease should receive primary vaccination or
re-vaccination with a second primary series beginning 4 weeks
after onset of disease.

Preterm Infants
Medically stable preterm infants§ should be vaccinated
beginning at age 2 months according to the schedule
recommended for other infants, on the basis of chronological age.

High Risk Groups
Persons considered at increased risk for invasive Hib disease
include those with functional or anatomic asplenia, HIV
infection, immunoglobulin deficiency (including
immunoglobulin G2 subclass deficiency), or early component
complement deficiency, recipients of a hematopoietic stem
cell transplant, and those receiving chemotherapy or radiation
therapy for malignant neoplasms. A single dose of any licensed
Hib conjugate vaccine should be administered to unimmunized
older children, adolescents, and adults who are asplenic or who
are scheduled for an elective splenectomy. Some experts suggest
administering a dose prior to elective splenectomy regardless
of prior vaccination history (22). On the basis of limited data
on the timing of Hib vaccination before splenectomy, experts
suggest vaccination at least 14 days before the procedure
(18,19,23) (Table 2).
Unimmunized children aged ≥60 months who have HIV
infection should receive 1 dose of Hib vaccine. Whether
HIV-infected children who have received a full 3 or 4 dose
vaccine series (depending on the vaccine type used for the
primary series) will benefit from additional Hib doses is
unknown. Because the incidence of Hib infections among
HIV-infected adults is low, Hib vaccine is not recommended
for adults with HIV infection (21,23) (Table 2).
Children aged 12–59 months who are at increased risk
for Hib disease (persons with asplenia, HIV infection,
immunoglobulin deficiency, early component complement
deficiency, or chemotherapy or radiation therapy recipients)
and who received no doses or only 1 dose of Hib conjugate
vaccine before age 12 months should receive 2 additional doses
of vaccine 8 weeks apart; children who received 2 or more doses
of Hib conjugate vaccine before age 12 months should receive
1 additional dose, at least 8 weeks after the last dose (Table 2).
Hib vaccination during chemotherapy or radiation therapy
should be avoided because of possible suboptimal antibody
§ Infants who do not require ongoing management for serious infection, metabolic

disease, or acute renal, cardiovascular, neurologic, or respiratory tract illness
and who demonstrate a clinical course of sustained recovery and pattern of
steady growth (90).

response. Patients vaccinated within 14 days of starting
immunosuppressive therapy or while receiving immunosuppressive
therapy should be considered unimmunized, and doses should
be repeated beginning at least 3 months following completion of
chemotherapy. Patients who were vaccinated more than 14 days
before chemotherapy do not require revaccination, with the
exception of recipients of a hematopoietic stem cell transplant
who should be revaccinated with a 3-dose regimen 6–12 months
after successful transplant, regardless of vaccination history (80);
at least 4 weeks should separate doses (Table 2).

Guidance for Vaccine Administration
Hib vaccines are administered intramuscularly in individual
doses of 0.5 mL. Adverse events occurring after administration
of any vaccine should be reported to VAERS. Reports can
be submitted to VAERS online, by facsimile, or by mail.
More information about VAERS is available by calling
1-800-822-7967 (toll-free) or online at http://vaers.hhs.gov.

Interchangeability of Vaccine Product
Studies have demonstrated that any combination of licensed
monovalent Hib conjugate vaccines for the primary and
booster doses provide comparable or higher antibody levels
than with the same monovalent product (33,44–46,51,91–93).
Therefore, licensed monovalent Hib conjugate vaccines are
considered interchangeable for the primary as well as the
booster doses (dose 3 or 4, depending on vaccine type used
for primary series) (18,94). Data on the interchangeability
of combination vaccines with other combination vaccines
or with monovalent vaccines are limited (52,63). Whenever
feasible, the same combination vaccine should be used for the
subsequent doses; however, if a different brand is administered,
the dose should be considered valid and need not be repeated.

Precautions and Contraindications
Adverse reactions to Hib-containing monovalent vaccines
are uncommon, usually mild, and generally resolve within
12–24 hours (41–43,49). Rates of adverse reactions to Hib
combination vaccines are similar to those observed with
separately administered vaccines (14,33,52–54). More
complete information about adverse reactions to a specific
vaccine is available in the package insert for each vaccine
and from CDC at http://www.cdc.gov/vaccines/vac-gen/
side-effects.htm.
Vaccination with a Hib-containing vaccine is contraindicated
in infants aged <6 weeks. Vaccination with a Hib-containing
vaccine is contraindicated among persons known to have a
severe allergic reaction to any component of the vaccine. The
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tip caps of the Hiberix prefilled syringes might contain natural
rubber latex, and the vial stoppers for Comvax, ActHib, and
PedvaxHIB contain natural rubber latex, which might cause
allergic reactions in persons who are latex-sensitive. Therefore,
vaccination with these vaccines is contraindicated for persons
known to have a severe allergic reaction to dry natural
rubber latex (48,50–52). The vial stoppers for Pentacel and
MenHibRix do not contain latex (63,95). Vaccination with
Comvax is contraindicated in patients with a hypersensitivity
to yeast (52).
As with all pertussis-containing vaccines, benefits and risk
should be considered before administering Pentacel to persons
with a history of fever ≥40.5oC, hypotonic-hyporesponsive
episode, persistent inconsolable crying lasting ≥3 hours within 48
hours after receipt of a pertussis-containing vaccine, or seizures
within 3 days after receiving a pertussis-containing vaccine (63).
Hib monovalent and combination conjugate vaccines are
inactivated vaccines and may be administered to persons with
immunocompromising conditions. However, immunologic
response to the vaccine might be suboptimal (18).

Guidance for Chemoprophylaxis
Secondary cases of Hib disease (illness occurring within
60 days of contact with a patient) occur but are rare.
Secondary attack rates are higher among household contacts
aged <48 months (2.1%), especially those aged <12 months
(6%) and <24 months (3%) (29). Data are conflicting on the
risk for secondary illness among child care contacts, but it is
thought to be lower than among household contacts (29).
Rifampin is recommended for chemoprophylaxis because it
achieves high concentrations in respiratory secretions and
eradicates nasopharyngeal carriage in >95% of carriers (96–99).
There are no guidelines for control measures around cases of
invasive nontype b H. influenzae disease. Chemoprophylaxis is
not recommended for contacts of persons with invasive disease
caused by nontype b H. influenzae because cases of secondary
transmission of disease have not been documented (100,101).

Index Patients with Invasive Hib Disease
Index patients who are treated with an antibiotic other than
cefotaxime or ceftriaxone and are aged <2 years should receive
rifampin prior to hospital discharge (22). Because cefotaxime
and ceftriaxone eradicate Hib colonization, prophylaxis is not
needed for patients treated with either of these antimicrobials.

Household Contacts
Rifampin chemoprophylaxis is recommended for index
patients (unless treated with cefotaxime or ceftriaxone) and all
household contacts in households with members aged <4 years
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who are not fully vaccinated or members aged <18 years who are
immunocompromised, regardless of their vaccination status (22).

Child Care Contacts
Rifampin chemoprophylaxis is recommended in child care
settings when two or more cases of invasive Hib disease have
occurred within 60 days and unimmunized or underimmunized
children attend the facility (22). When prophylaxis is indicated,
it should be prescribed for all attendees, regardless of age or
vaccine status, and for child care providers.

Conclusion
Hib disease was once a leading cause of bacterial meningitis
among U.S. children aged <5 years. As a result of the
introduction of Hib vaccines in the United States and sustained
high vaccine coverage, Hib disease is now rare, with rates
below the Healthy People 2020 objective. However, the risk
for invasive Hib disease continues among unimmunized and
underimmunized children, highlighting the importance of
full vaccination with the primary series and booster doses.
Although Hib disease is uncommon, continued H. influenzae
surveillance with complete serotyping data is necessary so that
all Hib cases are identified and appropriate chemoprophylaxis
measures can be taken.
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